Pharmacological management of type 2 diabetes: clinical considerations and future perspectives

Abstract

The management of type 2 diabetes continues to evolve with the historical glucocentric nature of care, paving the way toward more holistic and comorbidity-based management largely due to the advent of newer medications and trial data. Clinicians need to be aware that an understanding of not only the current treatment landscape but also the future developments in care and therapy is required in order to understand the best options for the management of their patients. This article will discuss current perspectives in the pharmacological management of type 2 diabetes, largely focusing on recent trial developments and associated future trials and molecules that may impact type 2 diabetes care in the near future.

Keywords

Type 2 diabetes / pharmacotherapy / cardiovascular disease / multimorbidity

References

[1] North EJ.Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.Curr Opin Cardiol2019;34:687-92 PMCID:PMC6876849

[2] Buse JB,Tsapas A.Erratum. 2019 Update to: management of hyperglycemia in type 2 diabetes, 2018. a consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD).Diabetes Care2020;43:1670 PMCID:PMC7411277

[3] Davies MJ,Collins BS.Management of hyperglycaemia in type 2 diabetes, 2022. a consensus report by the American Diabetes Association (ADA) and the European association for the study of diabetes (EASD).Diabetologia2022;65:1925-66 PMCID:PMC9510507

[4] Palmer SC,Mustafa RA.Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.BMJ2021;372:m4573 PMCID:PMC8764512

[5] NICE guideline NG28, Type 2 diabetes in adults: management Available from: https://www.nice.org.uk/guidance/ng28 [Last accessed on 6 May 2023]

[6] UK Prospective Diabetes Study (UKPDS) GroupEffect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).Lancet1998;352:854-65

[7] Rosenstock J,Kahn SE.Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial.Diab Vasc Dis Res2013;10:289-301

[8] Wallace MD.Optimizing the treatment of steroid-induced hyperglycemia.Ann Pharmacother2018;52:86-90

[9] Roberts A,Dhatariya K.Joint British Diabetes Societies (JBDS) for Inpatient CareManagement of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the joint British diabetes societies (JBDS) for inpatient care group.Diabet Med2018;35:1011-7

[10] Hattersley AT,Polak M.ISPAD clinical practice consensus guidelines 2018: the diagnosis and management of monogenic diabetes in children and adolescents.Pediatr Diabetes2018;19 Suppl 27:47-63

[11] Angwin C,Jones A.MASTERMIND consortiumTriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea-a MASTERMIND study protocol.BMJ Open2020;10:e042784 PMCID:PMC7754630

[12] Available from: https://www.easd.org/virtualmeeting/home.html#!resources/b-results-of-the-trimaster-trial-b [Last accessed on 24 May 2023]

[13] Dormandy JA,Eckland DJ.PROactive InvestigatorsSecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.Lancet2005;366:1279-89

[14] Young LH,Schwartz GG.IRIS InvestigatorsHeart failure after ischemic stroke or transient ischemic attack in insulin-resistant patients without diabetes mellitus treated with pioglitazone.Circulation2018;138:1210-20 PMCID:PMC6202153

[15] Lian J.Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis.Front Endocrinol2021;12:615409 PMCID:PMC8115121

[16] Stefan N.A global view of the interplay between non-alcoholic fatty liver disease and diabetes.Lancet Diabetes Endocrinol2022;10:284-96

[17] Matthews DR,Proot P,Stumvoll M.VERIFY study groupGlycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.Lancet2019;394:1519-29

[18] Strain WD,Brown P,Sinclair A.Diabetes and frailty: an expert consensus statement on the management of older adults with type 2 diabetes.Diabetes Ther2021;12:1227-47 PMCID:PMC8099963

[19] Available from: https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-announced-safety-review-has-found-type-2-diabetes-medicines-containing-saxagliptin-and#:~:text=On%20April%205%2C%202016%2C%20FDA,have%20heart%20or%20kidney%20disease [Last accessed on 23 May 2023]

[20] Zinman B,Lachin JM.EMPA-REG OUTCOME InvestigatorsEmpagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.N Engl J Med2015;373:2117-28

[21] Neal B,Mahaffey KW.CANVAS Program Collaborative GroupCanagliflozin and cardiovascular and renal events in type 2 diabetes.N Engl J Med2017;377:644-57

[22] Wiviott SD,Bonaca MP.DECLARE–TIMI 58 InvestigatorsDapagliflozin and cardiovascular outcomes in type 2 diabetes.N Engl J Med2019;380:347-57

[23] McMurray JJV,Inzucchi SE.DAPA-HF Trial Committees and InvestigatorsDapagliflozin in patients with heart failure and reduced ejection fraction.N Engl J Med2019;381:1995-2008

[24] Packer M,Butler J.EMPEROR-Reduced Trial InvestigatorsCardiovascular and renal outcomes with empagliflozin in heart failure.N Engl J Med2020;383:1413-24

[25] Perkovic V,Neal B.CREDENCE Trial InvestigatorsCanagliflozin and renal outcomes in type 2 diabetes and nephropathy.N Engl J Med2019;380:2295-306

[26] Heerspink HJL,Correa-Rotter R.DAPA-CKD Trial Committees and InvestigatorsDapagliflozin in patients with chronic kidney disease.N Engl J Med2020;383:1436-46

[27] Bauersachs J.SCORED and SOLOIST: the next scores for SGLT2 inhibitors.Cardiovasc Res2021;117:e49-51

[28] Anker SD,Filippatos G.EMPEROR-Preserved Trial InvestigatorsEmpagliflozin in heart failure with a preserved ejection fraction.N Engl J Med2021;385:1451-61

[29] Butler J,Jamal Siddiqi T.Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-preserved trial.Circulation2022;145:184-93 PMCID:PMC8763045

[30] Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-wider-range-patients-heart-failure [Last accessed on 24 May 2023]

[31] Available from: https://www.medicines.org.uk/emc/product/5441/smpc#gref [Last accessed on 24 May 2023]

[32] Hasegawa K.Are SGLT2 inhibitors effective against 'all' heart failure with preserved ejection fraction?.Eur Heart J Cardiovasc Pharmacother2022;8:E10

[33] Solomon SD,Claggett B.DELIVER Trial Committees and InvestigatorsDapagliflozin in heart failure with mildly reduced or preserved ejection fraction.N Engl J Med2022;387:1089-98

[34] Verma S,Zinman B.Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial.ESC Heart Fail2021;8:2603-7 PMCID:PMC8318423

[35] Berg DD,Docherty KF.Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction.JAMA Cardiol2021;6:499-507 PMCID:PMC7890451

[36] Packer M,Butler J.Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial.Circulation2021;143:326-36 PMCID:PMC7834905

[37] Voors AA,Teerlink JR.The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.Nat Med2022;28:568-74 PMCID:PMC8938265

[38] Kosiborod MN,Collins SP.Effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure: results from the EMPULSE trial.Circulation2022;146:279-88 PMCID:PMC9311476

[39] Koufakis T,Ajjan RA.The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: is the risk worth taking?.J Clin Pharm Ther2020;45:883-91

[40] Khunti K,Bhatt DL.Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: a perspective based on the updated evidence.Diabetes Obes Metab2022;24:2071-80

[41] Kosiborod MN,Furtado RHM.Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Diabetes Endocrinol2021;9:586-94 PMCID:PMC8294807

[42] Fralick M,Thiruchelvam D,Redelmeier DA.Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a nationwide cohort study of older adults with diabetes mellitus.Diabetes Obes Metab2021;23:950-60

[43] Available from: https://www.easd.org/media-centre/home.html%20#!resources/b-safety-and-efficacy-of-sglt2-inhibitors-in-over-70-years-old-type-2-diabetic-patients-1-year-of-follow-up-b-bac06cfd-6ee4-4476-a43d-096cb7d74cd4 [Last accessed on 24 May 2023]

[44] Yabe D,Suzaki K.Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes.BMJ Open2021;11:e045844 PMCID:PMC8031078

[45] Mai L,Qiu M.Association between prediabetes and adverse outcomes in heart failure.Diabetes Obes Metab2021;23:2476-83

[46] Kramer CK,Retnakaran R.Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis.Diabetologia2019;62:905-14

[47] Bailey CJ.Uric acid and the cardio-renal effects of SGLT2 inhibitors.Diabetes Obes Metab2019;21:1291-8

[48] Ferreira JP,Mattheus M.Empagliflozin and uric acid metabolism in diabetes: a post hoc analysis of the EMPA-REG OUTCOME trial.Diabetes Obes Metab2022;24:135-41 PMCID:PMC9293326

[49] McDowell K,Docherty KF.Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF.Eur J Heart Fail2022;24:1066-76 PMCID:PMC9540869

[50] Davies MJ,Vijapurkar U,Meininger G.Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.Diabetes Obes Metab2015;17:426-9 PMCID:PMC5054919

[51] Duell PB,Miller M.American Heart Association Council on ArteriosclerosisThrombosis and Vascular Biology; Council on Hypertension; Council on the Kidney in Cardiovascular Disease; Council on Lifestyle and Cardiometabolic Health; and Council on Peripheral Vascular DiseaseNonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American heart association.Arterioscler Thromb Vasc Biol2022;42:e168-85

[52] Androutsakos T,Bakasis AD et al.SGLT-2 Inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection.Int J Mol Sci2022;13:3107 PMCID:PMC8953901

[53] Takahashi H,Kawanaka M.Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD.Hepatol Commun2022;6:120-32 PMCID:PMC8710792

[54] Akuta N,Fujiyama S.Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: a 5-year follow-up study.Hepatol Commun2022;6:2286-97 PMCID:PMC9426401

[55] Takeshita Y,Harada K.Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial.Diabetes Care2022;45:2064-75 PMCID:PMC9472500

[56] Available from: https://kdigo.org/wp-content/uploads/2022/03/KDIGO-2022-Diabetes-Management-GL_Public-Review-draft_1Mar2022.pdf [Last accessed on 24 May 2023]

[57] Available from: https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/early-stop-chronic-kidney-disease-trial-efficacy [Last accessed on 24 May 2023]

[58] Bakris GL,Anker SD.FIDELIO-DKD InvestigatorsEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes.N Engl J Med2020;383:2219-29

[59] Pitt B,Agarwal R.FIGARO-DKD InvestigatorsCardiovascular events with finerenone in kidney disease and type 2 diabetes.N Engl J Med2021;385:2252-63

[60] Agarwal R,Pitt B.FIDELIO-DKD and FIGARO-DKD investigatorsCardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.Eur Heart J2022;43:474-84 PMCID:PMC8830527

[61] Neuen BL,Agarwal R.Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials.Circulation2022;145:1460-70

[62] Available from: https://clinicaltrials.gov/ct2/show/NCT05254002 [Last accessed on 24 May 2023]

[63] Marso SP,Consoli A.SUSTAIN-6 InvestigatorsSemaglutide and cardiovascular outcomes in patients with type 2 diabetes.N Engl J Med2016;375:1834-44

[64] Gerstein HC,Dagenais GR.REWIND InvestigatorsDulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.Lancet2019;394:121-30

[65] Gerstein HC,Dagenais GR.REWIND InvestigatorsDulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.Lancet2019;394:131-8

[66] Rossing P,Bakris G.The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.Nephrol Dial Transplant2023:gfad009

[67] Frías JP,Bajaj HS.Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.Lancet Diabetes Endocrinol2021;9:563-74

[68] Frias JP,Nevarez Ruiz L.Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11).Diabetes Care2021;44:765-73 PMCID:PMC7896253

[69] Davies M,Jeppesen OK.STEP 2 Study GroupSemaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.Lancet2021;397:971-84

[70] Rosenstock J,Frías JP.Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.Lancet2021;398:143-55

[71] Frías JP,Rosenstock J.SURPASS-2 InvestigatorsTirzepatide versus semaglutide Once weekly in patients with type 2 diabetes.N Engl J Med2021;385:503-15

[72] Ludvik B,Jódar E.Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.Lancet2021;398:583-98

[73] Battelino T,Rodríguez A.Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.Lancet Diabetes Endocrinol2022;10:407-17

[74] Gastaldelli A,Fernández Landó L,Brouwers B.Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.Lancet Diabetes Endocrinol2022;10:393-406

[75] Available from: https://clinicaltrials.gov/ct2/show/NCT04166773 [Last accessed on 24 May 2023]

[76] Parker VER,Wang T.Efficacy, safety, and mechanistic insights of cotadutide, a dual receptor glucagon-like peptide-1 and glucagon agonist.J Clin Endocrinol Metab2020;105:803-20

[77] Prato S,Pavo I.SURPASS-4 investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.Lancet2021;398:1811-24

[78] Sattar N,Pavo I.Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.Nat Med2022;28:591-8 PMCID:PMC8938269

[79] Available from: https://clinicaltrials.gov/ct2/show/NCT04255433 [Last accessed on 24 May 2023]

[80] Gerstein HC,Colhoun HM.The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.Lancet Diabetes Endocrinol2020;8:106-14

[81] Strain WD,James MA.Effects of semaglutide on stroke subtypes in type 2 diabetes: post hoc analysis of the randomized SUSTAIN 6 and PIONEER 6.Stroke2022;53:2749-57 PMCID:PMC9389936

[82] Available from: https://clinicaltrials.gov/ct2/show/NCT04777396 [Last accessed on 24 May 2023]

[83] Available from: https://clinicaltrials.gov/ct2/show/NCT05394519 [Last accessed on 24 May 2023]

[84] Available from: https://clinicaltrials.gov/ct2/show/NCT03574597 [Last accessed on 24 May 2023]

[85] Jastreboff AM,Ahmad NN.SURMOUNT-1 InvestigatorsTirzepatide once weekly for the treatment of obesity.N Engl J Med2022;387:205-16

[86] Kuchay MS,Mishra SK.Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).Diabetologia2020;63:2434-45

[87] Newsome PN,Cusi K.NN9931-4296 InvestigatorsA placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis.N Engl J Med2021;384:1113-24

[88] Available from: https://clinicaltrials.gov/ct2/show/NCT04822181 [Last accessed on 24 May 2023]

[89] Available from: https://clinicaltrials.gov/ct2/show/NCT05013229 [Last accessed on 24 May 2023]

[90] Heikkala E,Jokelainen J,Hagnäs M.Multimorbidity and achievement of treatment goals among patients with type 2 diabetes: a primary care, real-world study.BMC Health Serv Res2021;21:964 PMCID:PMC8442281

[91] Chiang JI,Li TC.Multimorbidity, mortality, and HbA1c in type 2 diabetes: a cohort study with UK and Taiwanese cohorts.PLoS Med2020;17:e1003094 PMCID:PMC7205223

[92] Xie F,Ma RC.Precision medicine in diabetes prevention, classification and management.J Diabetes Investig2018;9:998-1015 PMCID:PMC6123056

[93] Available from: https://www.fda.gov/medical-devices/in-vitro-diagnostics/precision-medicine [Last accessed on 24 May 2023]

[94] Nathan DM,Balasubramanyam A.GRADE Study Research GroupGlycemia reduction in type 2 diabetes - glycemic outcomes.N Engl J Med2022;387:1063-74

[95] Tye SC,Heerspink HJL.Precision medicine approaches for diabetic kidney disease: opportunities and challenges.Nephrol Dial Transplant2021;36:3-9 PMCID:PMC8216727